Has Laura della Torre, MD received payments from drug or device companies?

Yes. Drug and device makers reported $8,777 in general payments to Laura della Torre, MD across 410 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Laura della Torre, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Laura della Torre, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Laura della Torre, MD

Dermatology · Providence, RINPI 1215086988

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 410 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.

$8,777in general payments, 2019–2025

Across 410 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$1K
Johnson & Johnson$1K
LEO Pharma Inc.$1K
Arcutis Biotherapeutics, Inc.$820
Amgen$749
Lilly USA, LLC$637
plus $3K from 19 others

What the payments were for

Food & beverage$8,62698%
Education$1512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	63	$1,467
Johnson & Johnson	74	$1,199
LEO Pharma Inc.	46	$1,148
Arcutis Biotherapeutics, Inc.	38	$820
Amgen	35	$749
Lilly USA, LLC	23	$637
Novartis	32	$634
E.r. Squibb & Sons, L.L.C.	11	$260
Sun Pharmaceutical Industries Inc.	13	$245
Incyte Corporation	8	$192
Sanofi	10	$182
Galderma Laboratories, L.p.	5	$176
Pfizer	8	$176
Regeneron Healthcare Solutions, Inc.	6	$137
VYNE Pharmaceuticals Inc.	6	$133
Boehringer Ingelheim	4	$93
Bristol Myers Squibb	5	$91
Organon	6	$91
Dermavant Sciences, Inc.	4	$74
Aclaris Therapeutics, Inc.	3	$73
Ortho Dermatologics, A Division Of Bausch Health US, LLC	4	$69
UCB, Inc.	2	$66
Dermira, Inc.	1	$26
Paratek Pharmaceuticals, Inc.	1	$20
Strata Skin Sciences, Inc.	2	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

ZORYVE$250
Skyrizi$223
Rinvoq$113
Otezla$107

How this compares

$8,777 in reported general payments places this provider in the 80th percentile of 61 dermatology providers in Rhode Island.

See all dermatology providers in Rhode Island →

Medicare billing

Part B allowed, 2024

$103,363

Medicare patients

440

Services billed

1,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	32	$376,021
Clobetasol Propionate	178	$5,997
Ketoconazole	241	$3,515
Fluorouracil	52	$2,719
Metronidazole	43	$2,264
Tretinoin	33	$2,036
Clindamycin Phosphate	37	$1,520
Triamcinolone Acetonide	135	$1,431
Fluocinonide	44	$1,278
Clotrimazole	108	$1,244
Tacrolimus	12	$1,073
Ammonium Lactate	61	$1,048
Nystatin	33	$816
Ciclopirox	31	$609
Betamethasone Dipropionate	19	$574

Paid to pharmacies, not to this prescriber.

Other dermatology in Providence

Helena KuhnProvidence$63K
Martin WeinstockProvidence$62K
Farah MoustafaProvidence$51K
Abrar QureshiProvidence$38K
Scott HammermanProvidence$9K
Benjamin KahnProvidence$4K
Rachel HoffmannProvidence$4K
Jennie MugliaProvidence$2K
Daniella ReimannProvidence$2K
Gladys TelangProvidence$624

See the full list for Rhode Island →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →